Fundacion Jimenez Diaz and Autonoma University

Madrid, Spain

Fundacion Jimenez Diaz and Autonoma University

Madrid, Spain
SEARCH FILTERS
Time filter
Source Type

Gonzalez-Parra E.,Fundacion Jimenez Diaz and Autonoma University | Acena A.,IIS Fundacion Jimenez Diaz | Lorenzo O.,Fundacion Jimenez Diaz and Autonoma University | Tarin N.,Hospital Universitario Of Mostoles | And 14 more authors.
Journal of Bone and Mineral Metabolism | Year: 2015

Chronic kidney disease (CKD)–mineral and bone disorder (MBD) is characterized by increased circulating levels of parathormone (PTH) and fibroblast growth factor 23 (FGF23), bone disease, and vascular calcification, and is associated with adverse outcomes. We studied the prevalence of mineral metabolism disorders, and the potential relationship between decreased estimated glomerular filtration rate (eGFR) and CKD-MBD in coronary artery disease patients in a cross-sectional study of 704 outpatients 7.5 ± 3.0 months after an acute coronary syndrome. The mean eGFR (CKD Epidemiology Collaboration formula) was 75.8 ± 19.1 ml/min/1.73 m2. Our patients showed lower calcidiol plasma levels than a healthy cohort from the same geographical area. In the case of men, this finding was present despite similar creatinine levels in both groups and older age of the healthy subjects. Most patients (75.6 %) had an eGFR below 90 ml/min/1.73 m2 (eGFR categories G2–G5), with 55.3 % of patients exhibiting values of 60–89 ml/min/1.73 m2 (G2). PTH (r = −0.3329, p < 0.0001) and FGF23 (r = −0.3641, p < 0.0001) levels inversely correlated with eGFR, whereas calcidiol levels and serum phosphate levels did not. Overall, PTH levels were above normal in 34.9 % of patients. This proportion increased from 19.4 % in G1 category patients, to 33.7 % in G2 category patients and 56.6 % in G3–G5 category patients (p < 0.001). In multivariate analysis, eGFR and calcidiol levels were the main independent determinants of serum PTH. The mean FGF23 levels were 69.9 (54.6–96.2) relative units (RU)/ml, and 33.2 % of patients had FGF23 levels above 85.5 RU/ml (18.4 % in G1 category patients, 30.0 % in G2 category patients, and 59.2 % in G3–G5 category patients; p < 0.001). In multivariate analysis, eGFR was the main predictor of FGF23 levels. Increased phosphate levels were present in 0.7 % of the whole sample: 0 % in G1 category patients, 0.3 % in G2 category patients, and 2.8 % in G3–G5 category patients (p = 0.011). Almost 90 % of patients had calcidiol insufficiency without significant differences among the different degrees of eGFR. In conclusion, in patients with coronary artery disease there is a large prevalence of increased FGF23 and PTH levels. These findings have an independent relationship with decreased eGFR, and are evident at an eGFR of 60–89 ml/min/1.73 m2. Then, mild decreases in eGFR must be taken in consideration by the clinician because they are associated with progressive abnormalities of mineral metabolism. © 2015 The Japanese Society for Bone and Mineral Research and Springer Japan


PubMed | Rey Juan Carlos University, Hospital Universitario Fundacion Alcorcon, IIS Fundacion Jimenez Diaz, Autonomous University of Madrid and 3 more.
Type: Journal Article | Journal: Journal of bone and mineral metabolism | Year: 2016

Chronic kidney disease (CKD)-mineral and bone disorder (MBD) is characterized by increased circulating levels of parathormone (PTH) and fibroblast growth factor23 (FGF23), bone disease, and vascular calcification, and is associated with adverse outcomes. We studied the prevalence of mineral metabolism disorders, and the potential relationship between decreased estimated glomerular filtration rate (eGFR) and CKD-MBD in coronary artery disease patients in a cross-sectional study of 704 outpatients 7.53.0months after an acute coronary syndrome. The mean eGFR (CKD Epidemiology Collaboration formula) was 75.819.1ml/min/1.73m(2). Our patients showed lower calcidiol plasma levels than a healthy cohort from the same geographical area. In the case of men, this finding was present despite similar creatinine levels in both groups and older age of the healthy subjects. Most patients (75.6%) had an eGFR below 90ml/min/1.73m(2) (eGFR categories G2-G5), with 55.3% of patients exhibiting values of 60-89ml/min/1.73m(2) (G2). PTH (r=-0.3329, p<0.0001) and FGF23 (r=-0.3641, p<0.0001) levels inversely correlated with eGFR, whereas calcidiol levels and serum phosphate levels did not. Overall, PTH levels were above normal in 34.9% of patients. This proportion increased from 19.4% in G1 category patients, to 33.7% in G2 category patients and 56.6% in G3-G5 category patients (p<0.001). In multivariate analysis, eGFR and calcidiol levels were the main independent determinants of serum PTH. The mean FGF23 levels were 69.9 (54.6-96.2) relative units (RU)/ml, and 33.2% of patients had FGF23levels above 85.5RU/ml (18.4% in G1 category patients, 30.0% in G2 category patients, and 59.2% in G3-G5 category patients; p<0.001). In multivariate analysis, eGFR was the main predictor of FGF23 levels. Increased phosphate levels were present in 0.7% of the whole sample: 0% in G1 category patients, 0.3% in G2 category patients, and 2.8% in G3-G5 category patients (p=0.011). Almost 90% of patients had calcidiol insufficiency without significant differences among the different degrees of eGFR. In conclusion, in patients with coronary artery disease there is a large prevalence of increased FGF23 and PTH levels. These findings have an independent relationship with decreased eGFR, and are evident at an eGFR of 60-89ml/min/1.73m(2). Then, mild decreases in eGFR must be taken in consideration by the clinician because they are associated with progressive abnormalities of mineral metabolism.

Loading Fundacion Jimenez Diaz and Autonoma University collaborators
Loading Fundacion Jimenez Diaz and Autonoma University collaborators